Mark Lebwohl, MD

(1:48)

Dr. Mark Lebwohl, 2021 American Skin Association Research Achievement Award

(43)

Mark Lebwohl, MD - Apremilast as an Off-Label Therapeutic Agent

(1:57)

Mark Lebwohl, MD - What is topical roflumilast?

(1:1econd)

Psoriasis: Which Drug for Which Patient? Mark Lebwohl, MD

(2:38)

Commit to Cure: Dr. Mark Lebwohl Tribute

(7:16)

PSORIASIS (AVOID These 7 Things) 2024

(15:23)

Gluten Intolerance Symptoms (9 EARLY SIGNS You Are Gluten Intolerant!) *Non-Celiac*

(9:36)

Natural Treatments For Psoriasis | Dr. Josh Axe

(7:37)

BIOLOGICS FOR PSORIASIS REVIEW 💉 : How I 'CURED' my PSORIASIS fast!

(6:53)

TOWN HALL: Answering FAQs and Exploring New RESEARCH on CELIAC Disease GENETIC TESTING and BIOPSIES

(1:2:21)

Unlocking the Secrets of Cellular-Level Skin Health | Alan Widgerow of Galderma

(41:17)

Unlock the Benefits of Vitamin E

(18:48)

Lecture-15: Biologics in Psoriasis. Rook's chapter 35.

(25:20)

A Day in the Life: Munich Student at LMU/TUM

(11:7)

Mark Lebwohl, MD - What is the overall tolerability and most common side effects of roflumilast?

(54)

Mark Lebwohl, MD - What were the efficacy outcomes for roflumilast in Phase 3 clinical trials?

(34)

Break Through the Barriers to Healthcare Dr Mark Lebwohl

(7:42)

Mark Lebwohl, MD - Who is topical roflumilast approved for?

(17)

Mark Lebwohl, MD - What are the advantages of a once-daily, steroid-free topical?

(31)

Mark Lebwohl, MD - What are your thoughts on the formulation of topical roflumilast for patients?

(29)

Mark Lebwohl, MD - What is the I-IGA Success endpoint, and why is it important?

(1:11)

DermTV - Psoriasis 101 with Dr. Mark Lebwohl [DermTV.com Epi #384]

(7:33)

Mark Lebwohl, MD - What is the long-term safety and efficacy data of topical roflumilast?

(18)

FC21 - Ustekinumab and IL-23 Blockers, Mark Lebwohl, MD

(1:25)

Mark Lebwohl, MD - Which efficacy outcomes for topical roflumilast do you find most compelling?

(50)

FCPANP19 - Mark Lebwohl Meeting Intro

(27)

1 Mark Lebwohl, MD, FAAD

(22:48)

Digital Highlights Hub | Dr Mark Lebwohl, MD

(7:40)